Skip to content
1st Counsel – Lifestyle
Author:
Shattuck Labs, Inc.
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
June 5, 2026
←
Previous Page
1
2